May 1978

Decreased Platelet Monoamine Oxidase Activity in Chronic Schizophrenia, Shown With Novel Substrates

Author Affiliations

From the Departments of Psychiatry (Dr Berrettini) and Pharmacology (Drs Prozialeck and Vogel), and the Schizophrenia Research and Treatment Center (Drs Berrettini and Vogel), Jefferson Medical College, Philadelphia.

Arch Gen Psychiatry. 1978;35(5):600-605. doi:10.1001/archpsyc.1978.01770290082007

• Platelet monoamine oxidase (MAO) was kinetically evaluated in chronic schizophrenics and matched controls, using substrates of major physiologic importance and substrates of particular interest in the study of schizophrenia, such as serotonin (5-HT),N,N-dimethyltryptamine(DMT), 5-methoxytryptamine (5-MT), and dopamine (DA). Substrates were measured at six concentrations; values for maximal velocity (Vmax) and Michaelis constant (Km) were obtained by using Lineweaver-Burk plots.

The Vmax was decreased for all substrates in chronic schizophrenia and the Km was decreased for DA, 5-HT, and DMT, but remained unchanged for 5-MT. The value of Km/Vmax was similar for schizophrenics and normal persons when DA, 5-HT, and DMT were used as substrates, which may indicate that "uncompetitive" inhibition is responsible for the observed decrease in activity among chronic schizophrenics. The finding of a decreased Vmax but unchanged Km with 5-MT would be consistent with noncompetitive inhibition.